Lecture 3 — Research Ethics

Part B: Vulnerability, Equipoise, Money, and Trustworthy Knowledge

Author

Affiliation

Brendan Shea, PhD

An Introduction to Bioethics.

0.1 Before We Start

You sit on a research review board. This protocol lands on your desk:

A 12-month placebo-controlled trial of a new Alzheimer’s drug. Participants: residents of one memory-care facility. Consent: signed by adult children as surrogates. Site chosen because “follow-up is easy — they don’t move.”

• Would you approve it? What bothers you, if anything?
• What single change would you require first?
• Is “easy follow-up” ever a fair reason to pick a population?

1 Where We Left Off

1.1 The New Question

• Part A explained how trials work and how to read their results
• The rules that protect participants were written after real abuses
• Part B asks a harder question: when does reviewed, legal, well-funded research still wrong people?
• One idea organizes the whole lecture: vulnerability — who can be pressured, and who pays when knowledge is the goal

1.2 Today

By the end of Part B, you will be able to:

• Define vulnerability as a matter of power and pressure, not personality, using a working list of types
• Apply the Belmont principles as concrete IRB review questions
• Explain clinical equipoise as the moral license that both starts and ends a trial
• Judge when placebo controls are and are not defensible, including across rich and poor settings
• Show how commercial funding distorts research, using the Markingson case
• Explain why so many published findings fail to replicate — and how AI magnifies the threat

1.3 Three Abuses, Three Protections

Modern research protections were built one scandal at a time.

Case	The wrong	What it forced into place
Nazi experiments	No real consent; extreme harm	Voluntary consent; Nuremberg (Nuremberg Military Tribunals 1947)
Willowbrook	Dependent children; coercive setting	Vulnerable-population protection; independent review (Jonsen 1998)
Tuskegee	Deception; withheld treatment; racist selection	Belmont: respect, beneficence, justice (Brandt 1978; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 1979)

2 What Makes a Subject Vulnerable?

2.1 Vulnerability Is Pressure, Not Personality

• Every case above shares one feature. The people studied could not freely say no.
• Vulnerability is not a kind of person. It is a kind of situation.
• The questions that matter: who depends on whom? Who can walk away? What would refusing cost?
• Justice cuts both ways. Wrongful exploitation of the vulnerable and wrongful exclusion from research are both failures.

2.2 A Working List of Vulnerabilities

Kenneth Kipnis’s types name what kind of pressure a participant is under (Kipnis 2001).

Type	The pressure	Example
Cognitive	Cannot fully understand or weigh the choice	Dementia; acute psychosis
Juridic	Under the authority of someone who wants enrollment	Prisoners; committed patients
Deferential	Socially unable to refuse a trusted figure	Patient recruited by own physician
Medical	Desperate; no good alternative	Terminal illness, “nothing left to try”
Allocational	Poor; the study is a path to care or money	Payment covers rent; trial is the only clinic
Infrastructural	The setting cannot deliver on promises	Weak health system; no drug supply after the trial

A wealthy patient recruited by her own oncologist is deferentially and medically vulnerable, though she is on no protected list.

2.3 Thought Question

You are on an IRB reviewing a vaccine study.

• Disease rates are high in prisons.
• Researchers want to recruit incarcerated people because follow-up will be easy.
• They plan a modest payment and better clinic access for participants.

1. Which types of vulnerability are in play here at once?
2. Is this fair inclusion, opportunistic targeting, or both?
3. Would excluding prisoners entirely also create a justice problem?

2.4 After You’ve Discussed

Note

• Name the pressures, then design against them. This study mixes juridic (incarceration), allocational (payment, clinic access), and infrastructural (will the vaccine reach them afterward?) vulnerability.
• Inclusion and protection can conflict. Banning prison research protects against coercion. It can also deny prisoners the benefits of studies aimed at their own disease.

3 Belmont, Put to Work

3.1 Belmont in One Slide

• The Belmont Report (1979) named three principles (National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 1979)
• Respect for persons → real consent; extra care where vulnerability is highest
• Beneficence → minimize harm; justify risk against benefit
• Justice → who bears the burdens, who gets the benefits
• Each becomes a concrete question an IRB must ask of every study

The Belmont Report, 1979. U.S. Department of Health, Education, and Welfare. Public domain.

3.2 Back to the Memory-Care Protocol

Return to the Alzheimer’s trial from the start of class: one memory-care facility, consent signed by adult children, a site chosen because “they don’t move.”

1. Which vulnerability types apply?
2. Score it on each Belmont principle. Where is it weakest?
3. Has your answer about approving it changed?

4 Equipoise: The Moral Clock on a Trial

4.1 The Clock Runs Out

• Part A’s license to randomize was clinical equipoise: the expert community’s honest “we do not yet know,” a standard Benjamin Freedman named in 1987 (Freedman 1987)
• Equipoise is not permanent. Evidence builds up while the trial runs.
• An independent monitoring board can stop a trial early for three reasons:

Trigger	What it means	Why stopping is required
Harm	One arm is clearly hurting people	Continuing knowingly harms participants
Benefit	One arm is clearly better	Keeping the other arm is no longer fair
Futility	The question cannot be answered	More risk buys no knowledge

• When the uncertainty resolves, the moral license expires. The trial must end.

4.2 Stopping Early Is Not Free

A counterintuitive fact. Trials stopped early for benefit tend to overstate how well the treatment works.

Random luck swings hardest in small samples. A trial that stops the moment results look great may have stopped on a lucky high point. This is why monitoring boards use strict statistical rules, not “it looks good enough.” Stopping early is both an ethical and a scientific judgment: it protects participants and leaves the public with weaker evidence.

4.3 Where Equipoise Runs Out

Equipoise does not answer every research-ethics question.

• Phase I trials have no arms to compare. A first-in-human dose-finding study exposes participants to risk for little personal benefit. The framework there is risk-benefit plus informed consent.
• Miller and Brody’s critique. Equipoise treats the investigator as the participant’s doctor, with a duty not to give a worse option. But research aims at knowledge for future patients. On their view, equipoise imports the therapeutic misconception into the rulebook (Miller and Brody 2003).
• Equipoise fits the middle of research ethics, comparative trials of real treatments, and fits the edges poorly.

5 Placebo, Poverty, and Global Research

5.1 Helsinki’s Placebo Rule

• The Declaration of Helsinki says new treatments should usually be tested against the best proven option (World Medical Association 2024)
• Placebo is acceptable if no proven treatment exists, or for strong scientific reasons, but not if participants risk serious or permanent harm by going without proven treatment
• Most fights about that last condition are fights about whether equipoise exists
• “A proven treatment already exists” means there is no real uncertainty, so a placebo arm sends people to a known-worse option
• “The proven treatment cannot be delivered here” means uncertainty about feasible options remains

5.2 The AZT Trials in Five Lines

• In 1994, a long-course AZT regimen reduced mother-to-baby HIV transmission
• That regimen was expensive and hard to deliver in many low-resource settings
• Later trials tested shorter, cheaper regimens, often against placebo
• Critics: this withheld a known effective treatment (Lurie and Wolfe 1997)
• Defenders: the real question was what feasible strategy could work where the long regimen was not available (Varmus and Satcher 1997)

HIV-1 budding from a lymphocyte. CDC Public Health Image Library, #10000 (C. Goldsmith). Public domain.

5.3 Two Famous Positions

Lurie and Wolfe (Lurie and Wolfe 1997)

• A proven regimen already existed
• Placebo meant withholding known benefit
• Poverty must not lower the ethical standard
• Poorer countries should not get weaker protections

Varmus and Satcher (Varmus and Satcher 1997)

• The long regimen was not realistically deliverable
• A shorter regimen might still save lives at scale
• The relevant comparison had to include feasibility
• Blocking the trial preserves principle but blocks benefit

5.4 A Placebo Decision Tree

A simple placebo decision tree. Each diamond is really a question about whether genuine equipoise exists. Real IRB review is more detailed.

5.5 Thought Question

You are on an ethics committee in 1997 reviewing a short-course AZT trial in Uganda.

• In the sponsor country, the long-course regimen already works.
• In the host country, that regimen is too expensive and complex for everyday use.
• The study compares a shorter regimen to placebo.

1. Is there real equipoise here — and equipoise about what?
2. Does local unavailability change what researchers ethically owe participants?
3. What is owed after the study — do participants keep what worked?

5.6 After You’ve Discussed

Note

This is allocational and infrastructural vulnerability by design.

• “Local standard” describes the world; it does not settle what is owed. A study can be feasible, even locally standard, and still exploitative — poverty is not a discount on human protections.
• Post-trial access is part of the ethics, not cleanup. Proving a regimen works and then taking it away uses the host community (Emanuel et al. 2004; World Medical Association 2024).

6 Research Without a Trial: Tissue and Data

6.1 Henrietta Lacks

• In 1951 Henrietta Lacks, a Black woman, was treated for cervical cancer at Johns Hopkins
• Without her knowledge, cells from her tumor were taken and grown
• They became HeLa, the first immortal human cell line, used in countless studies and products
• She was never asked. Her family was not told for decades, and shared in none of the benefit.
• No drug, no placebo, no “arm,” and still a major research-ethics failure. The vulnerability here was never being asked at all.

HeLa cells, fluorescence micrograph. National Institutes of Health. Public domain.

The image is of her cells, not of her. That is a choice, given what this slide is about.

6.2 What the Rules Now Require

• US human-subjects research follows the Common Rule, rewritten in 2018 (US Department of Health and Human Services 2018)
• Consent forms must open with a short “key information” summary in plain language
• Broad consent: a person can agree once to future, unspecified research on stored samples and data
• Most multi-site studies now use a single IRB instead of one per site
• Broad consent is more honest than silence. It is also ethically thinner than asking each time.

6.3 Thought Question

You give a blood sample for a routine test. A leftover vial is stored. Years later it is used — with your name removed — in genetic research and a profitable diagnostic. You were never asked. A broad intake form said “samples may be used for research.”

1. Was that consent meaningful?
2. Do you have a claim to a say — or a share — in what was discovered?
3. Is “deidentified” enough, when the sample is DNA that can re-identify you and your relatives?

6.4 After You’ve Discussed

Note

• Consent for this study is not consent for all future research. Tissue and data banks rely on broad consent. Useful, but ethically thinner than specific consent.
• Benefit-sharing is part of justice. If people make a discovery possible, who profits is an ethical question, not an afterthought.
• “Deidentified” weakens but does not erase the stake. Genomic data can re-identify, and can implicate relatives who never agreed.

7 When Money Recruits: Commercial Funding

7.1 The Structural Conflict

• Most clinical trials are now funded by the companies that profit if the drug succeeds
• Industry funding is not wrong by itself. But it builds in a conflict of interest.
• Watch three roles: who funds, who recruits, and who reviews
• The danger peaks when the same people, paid by the sponsor, also treat and enroll the patient
• This is deferential and medical vulnerability meeting a financial incentive

7.2 The Markingson Case

Dan Markingson, University of Minnesota, 2003–2004. A young man with acute psychosis was placed under an involuntary commitment order. His treating psychiatrist enrolled him in the industry-funded CAFÉ antipsychotic trial. He was facing commitment to a state hospital if he did not cooperate with his treatment team. His mother repeatedly warned that he was getting worse. He died by suicide during the study.

7.3 What the 2015 Review Found

• Markingson was, in the state auditor’s words, “extraordinarily vulnerable” — committed, psychotic, with no real freedom to refuse (Office of the Legislative Auditor, State of Minnesota 2015)
• Investigators and the IRB chair had financial ties to the sponsor. That gave them a reason to enroll and keep subjects (Office of the Legislative Auditor, State of Minnesota 2015)
• The University’s review of his death was shallow. It did not look at medical records or seek outside information.
• Bioethicist Carl Elliott spent years pressing for accountability. The university pushed back (Elliott 2010).
• Every vulnerability type from earlier is here at once: cognitive, juridic, deferential, medical

7.4 Disclosure Is Not a Firewall

A well-designed system does not rely on good intentions. It builds structure.

Weak safeguard	Stronger safeguard
Investigator discloses COI on a form	Recruitment done by someone with no stake in enrollment
Sponsor analyzes its own data	Independent monitoring board and statisticians
Treating doctor also enrolls the patient	Separation of the care role from the research role
Institution investigates itself	Outside, empowered review when harm occurs

7.5 Thought Question

A patient newly diagnosed with a serious illness is offered a trial by the physician she trusts most — her own specialist. The specialist receives per-patient payments from the sponsor for each person enrolled.

1. Which vulnerability types is she under, before any form is signed?
2. Is disclosure of the payment enough to fix the problem? Why or why not?
3. What single structural change would most reduce the conflict?

7.6 After You’ve Discussed

Note

• Conflict of interest is structural, not just moral. Honest people in a bad structure still produce biased enrollment.
• Disclosure is the floor, not the fix. Telling someone about a conflict does not neutralize it. Separating the roles does.
• The treating clinician is the highest-pressure recruiter, which is why independent recruitment and review exist.

8 When the Knowledge Is the Problem

8.1 Protecting Participants Is Not Enough

• A clean consent process does not guarantee trustworthy knowledge
• The US Office of Research Integrity names three core wrongs:
  • Fabrication — making up data
  • Falsification — manipulating data, images, or results
  • Plagiarism — passing off others’ work as your own
• A faked study can change treatment for millions before anyone notices. The wronged party is now the future patient.

8.2 Why So Many Findings Are False

A landmark paper by John Ioannidis argued that most published findings can be wrong (Ioannidis 2005). Four reasons:

• Low base rate — most hypotheses tested are false to start with
• Small studies — easily swung by chance
• Researcher flexibility — p-hacking (trying analyses until one crosses the line) and HARKing (hypothesizing after the results are known). Neither requires lying (Simmons et al. 2011). Part A’s ISIS-2 showed the mechanism: test enough subgroups and aspirin “fails” for Geminis.
• Publication bias — positive results get printed. Null results vanish.

8.3 It Is Systemic, Not Rare

• Psychology: a large replication project reproduced only about 39% of published findings (Open Science Collaboration 2015). The casualties included power posing, ego depletion, and social priming: TED talks, textbooks, and bestsellers.
• Preclinical cancer: one team could confirm just 6 of 53 landmark studies (Begley and Ellis 2012)
• These are not fringe journals. They are the literature clinicians rely on.
• “Published” and “peer-reviewed” are a floor, not a guarantee

Power posing: a “confident” stance was said to change hormones and risk-taking; large replications found no reliable effect. Ego depletion: willpower as a fuel that runs out; a 23-lab preregistered test found the effect near zero. Social priming: reading “elderly” words was said to make people walk slower; it did not replicate.

8.4 The Alzheimer’s Case

In 2006, a Nature paper named a specific amyloid protein, **Aβ*56, as a cause of memory loss. It became one of the most-cited Alzheimer’s papers of its era and helped lock in the “amyloid hypothesis” that steered roughly 16 years** of funding and drug development.

In 2022, a six-month Science investigation found that key images in that paper, and in many related ones, appear to have been manipulated (Piller 2022).

Beta-amyloid plaque formation. National Institute on Aging, NIH. Public domain.

• Through those years amyloid-targeting drugs failed trial after trial, and participants received infusions with real risks: brain swelling and microbleeds
• A possibly faked result may have redirected a field while patients volunteered for drugs built on it

8.5 Medicine: Treatments Patients Received That Didn’t Work

A review led by Vinay Prasad found that about 40% of established practices tested over a decade were later contradicted (Prasad et al. 2013).

Treatment	What patients went through	What rigorous trials showed
Knee arthroscopy for arthritis	Real surgery, anesthesia, recovery	No better than sham surgery (Moseley et al. 2002)
Hormone therapy “for the heart”	Years of daily medication	Raised heart disease, stroke, breast cancer (Writing Group for the Women’s Health Initiative Investigators 2002)
Vertebroplasty (spinal fracture)	Cement injected into the spine	No better than a sham procedure (Kallmes et al. 2009)
Stents for stable chest pain	An invasive cardiac procedure	No better than a placebo procedure at improving exercise time (Al-Lamee et al. 2018)

Each was standard, paid for, and sincerely recommended.

8.6 The AI Turn

• Surgisphere, 2020: The Lancet and NEJM pulled COVID papers built on a huge hospital database. No one could audit it. It likely never existed. Faked big data, accepted because it looked official.
• AI now makes this cheaper. Faked images. Synthetic “data.” Fluent paper-mill manuscripts at scale.
• It also makes p-hacking faster — an automated search across thousands of model variants
• Counter-tools exist (image forensics, statistical screening). But detection lags creation.
• For a clinician: source and replication matter more than polish. A confident, well-written result is not a true one.

8.7 Thought Question

A landmark drug trial is later found to contain manipulated data. Thousands of patients were treated based on it. (Recall the opioid story from Part A: a single misread letter, heavily promoted, helped launch a crisis.)

1. Who was wronged — the study’s participants, future patients, or both?
2. Is faking data a worse research-ethics violation than a consent failure, or just a different one?
3. Why does the system usually catch this slowly — and what would catch it sooner?

8.8 After You’ve Discussed

Note

• Integrity is a subject-protection issue too. A false result is not just an academic error. It is the knee surgery, the hormone pill, the amyloid infusion that thousands of real people endured for nothing.
• The safeguards are thin by design — science runs on trust and occasional replication — so the fixes are structural: preregistration, data sharing, independent replication, faster retractions.

9 Wrapping Up Part B

9.1 Wrapping Up Part B

Research ethics is the study of how the search for knowledge can wrong people — and how to design against it.

Vulnerability is the spine. It is power and pressure, not personality. That is why consent must be real. It is why equipoise — the standard, if contested, license for most RCTs — both starts and ends a trial. It is why placebo and global trials turn on feasibility and post-trial duties. It is why commercial funding needs structural firewalls, not just disclosure. And it is why a replication crisis amplified by AI is itself a subject-protection problem.

Ethical research is not research with a signature. It is research designed so that the people who make knowledge possible — and the future patients who will rely on it — are treated as persons first.

9.2 Review Questions

Write a brief answer to each, or use them as discussion prompts.

Recall

What does Belmont’s Justice principle ask an IRB to check when it picks who gets studied? Then give one example each of cognitive and allocational vulnerability.

Apply

A biotech company wants to collect DNA from children in foster care to study rare brain conditions. State caseworkers — not the children’s parents — will sign the consent. Name two things an IRB should worry about before approving this study.

Debate

A drug that works is standard care in rich countries but unavailable in a poor country. Is it acceptable to run a placebo-controlled trial of a new drug there, given that the standard drug is out of reach anyway? Defend your answer.

9.3 Key Terms

• Belmont Report (1979) — names the three principles for human-subjects research: respect for persons, beneficence, and justice.
• Respect for persons — the Belmont principle requiring informed consent and extra protections for those with limited autonomy.
• Beneficence (in research) — minimize risks, maximize benefits, keep a favorable risk-benefit ratio.
• Justice (Belmont) — fair distribution of the benefits and burdens of research. Operationalized as Fair Subject Selection.
• Fair Subject Selection — recruiting populations because they bear on the scientific question. Not because they are convenient or powerless.
• Vulnerability — features of a subject or group that limit their ability to protect their own interests in a study.
• Cognitive vulnerability (Kipnis) — limits on capacity to understand or evaluate the study (e.g., children, intellectual disability).
• Allocational vulnerability (Kipnis) — being in a position where study participation is hard to refuse because resources, services, or status depend on it.
• Clinical equipoise — real uncertainty in the expert community about whether one trial arm is better than the other. The standard license for randomizing in comparative trials; contested at the edges (Phase I, early stopping, the Miller-Brody critique).
• Declaration of Helsinki — the WMA’s evolving statement of physicians’ duties in research, including consent and post-trial obligations.
• Common Rule — the US federal regulation (45 CFR 46) governing federally funded human-subjects research. The framework IRBs apply.
• IRB (Institutional Review Board) — the local committee that reviews protocols against these principles before research may proceed.

9.4 References

Al-Lamee, Rasha, David Thompson, Hakim-Moulay Dehbi, et al. 2018. “Percutaneous Coronary Intervention in Stable Angina (ORBITA): A Double-Blind, Randomised Controlled Trial.” The Lancet 391 (10115): 31–40.

Begley, C. Glenn, and Lee M. Ellis. 2012. “Raise Standards for Preclinical Cancer Research.” Nature 483 (7391): 531–33. https://doi.org/10.1038/483531a.

Brandt, Allan M. 1978. “Racism and Research: The Case of the Tuskegee Syphilis Study.” Hastings Center Report 8 (6): 21–29. https://doi.org/10.2307/3561468.

Elliott, Carl. 2010. The Deadly Corruption of Clinical Trials. Mother Jones, September/October 2010. https://www.motherjones.com/environment/2010/09/dan-markingson-drug-trial-astrazeneca/.

Emanuel, Ezekiel J., David Wendler, Jack Killen, and Christine Grady. 2004. “What Makes Clinical Research in Developing Countries Ethical? The Benchmarks of Ethical Research.” The Journal of Infectious Diseases 189 (5): 930–37. https://doi.org/10.1086/381709.

Freedman, Benjamin. 1987. “Equipoise and the Ethics of Clinical Research.” New England Journal of Medicine 317 (3): 141–45. https://doi.org/10.1056/NEJM198707163170304.

Ioannidis, John P. A. 2005. “Why Most Published Research Findings Are False.” PLoS Medicine 2 (8): e124. https://doi.org/10.1371/journal.pmed.0020124.

Jonsen, Albert R. 1998. The Birth of Bioethics. Oxford University Press.

Kallmes, David F., Bryan A. Comstock, Patrick J. Heagerty, et al. 2009. “A Randomized Trial of Vertebroplasty for Osteoporotic Spinal Fractures.” New England Journal of Medicine 361 (6): 569–79. https://doi.org/10.1056/NEJMoa0900563.

Kipnis, Kenneth. 2001. “Vulnerability in Research Subjects: A Bioethical Taxonomy.” In Ethical and Policy Issues in Research Involving Human Participants, Volume II. National Bioethics Advisory Commission.

Lurie, Peter, and Sidney M. Wolfe. 1997. “Unethical Trials of Interventions to Reduce Perinatal Transmission of the Human Immunodeficiency Virus in Developing Countries.” New England Journal of Medicine 337 (12): 853–56. https://doi.org/10.1056/NEJM199709183371212.

Miller, Franklin G., and Howard Brody. 2003. “A Critique of Clinical Equipoise: Therapeutic Misconception in the Ethics of Clinical Trials.” Hastings Center Report 33 (3): 19–28.

Moseley, J. Bruce, Kimberly O’Malley, Nancy J. Petersen, et al. 2002. “A Controlled Trial of Arthroscopic Surgery for Osteoarthritis of the Knee.” New England Journal of Medicine 347 (2): 81–88. https://doi.org/10.1056/NEJMoa013259.

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1979. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. U.S. Department of Health, Education, and Welfare. https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/index.html.

Nuremberg Military Tribunals. 1947. The Nuremberg Code. Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10.

Office of the Legislative Auditor, State of Minnesota. 2015. A Clinical Drug Study at the University of Minnesota Department of Psychiatry: The Dan Markingson Case. Special Review, March 19, 2015. https://www.auditor.leg.state.mn.us/sreview/markingson.pdf.

Open Science Collaboration. 2015. “Estimating the Reproducibility of Psychological Science.” Science 349 (6251): aac4716. https://doi.org/10.1126/science.aac4716.

Piller, Charles. 2022. “Blots on a Field?” Science 377 (6604): 358–63. https://doi.org/10.1126/science.add9993.

Prasad, Vinay, Andrae Vandross, Caitlin Toomey, et al. 2013. “A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices.” Mayo Clinic Proceedings 88 (8): 790–98. https://doi.org/10.1016/j.mayocp.2013.05.012.

Simmons, Joseph P., Leif D. Nelson, and Uri Simonsohn. 2011. “False-Positive Psychology: Undisclosed Flexibility in Data Collection and Analysis Allows Presenting Anything as Significant.” Psychological Science 22 (11): 1359–66. https://doi.org/10.1177/0956797611417632.

US Department of Health and Human Services. 2018. Federal Policy for the Protection of Human Subjects (“the Common Rule”). Code of Federal Regulations, Title 45, Part 46. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule/index.html.

Varmus, Harold, and David Satcher. 1997. “Ethical Complexities of Conducting Research in Developing Countries.” New England Journal of Medicine 337 (14): 1003–5. https://doi.org/10.1056/NEJM199710023371411.

World Medical Association. 2024. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Participants. Adopted by the 75th WMA General Assembly, Helsinki, Finland. https://www.wma.net/policies-post/wma-declaration-of-helsinki/.

Writing Group for the Women’s Health Initiative Investigators. 2002. “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial.” JAMA 288 (3): 321–33. https://doi.org/10.1001/jama.288.3.321.